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Background
Induction and persistence of vaccine induced antibodies
among recipients of HIV vaccines may pose a diagnostic
challenge. We investigated the performance and useful-
ness of rapid tests for the detection of HIV antibodies
among healthy HIV-uninfected people previously
enrolled in a phase I HIV vaccine trial in Kigali, Rwanda.
Methods
Between September 2005 and May 2006, 57 healthy, HIV-
uninfected adult volunteers (36 males and 21 females)
were enrolled in a phase-I, randomized, placebo-control-
led HIV vaccine trial at Projet San Francisco in Kigali,
Rwanda. At the end of the trial and after unblinding, all
volunteers were asked to participate in a long-term follow-
up study for continuous clinical and immunological eval-
uation. HIV testing using three rapid tests (Abbott Deter-
mine™ HIV1-2, Trinity Biotech Capillus™ HIV-1/HIV-2
and Trinity Biotech Uni-GoldTM HIV) and an ELISA test
(Bio-Mérieux Vironostika HIV Uniform II Ag/Ab) was per-
formed every three months.
Results
Of the 57 volunteers enrolled in the trial, 13 received pla-
cebo, 13 received one dose of a recombinant HIV-1 aden-
oviral type 5 vector vaccine (rAd5), and 31 received 3
doses of an HIV-1 DNA plasmid vaccine followed by one
dose of rAd5. Of these 44 vaccine recipients, 41 produced
HIV antibodies during the trial period. After 18 to 24
months of follow-up, 32 volunteers still test HIV-positive
on the ELISA test, but only one volunteer tested persist-
ently HIV positive using HIV rapid tests.
Conclusion
Most vaccine recipients produced HIV antibodies that
have persisted for at least two years. These vaccine-
induced antibodies are predominantly detected by a com-
mercial ELISA test, and not by the three HIV rapid tests
that were evaluated. This study suggests that HIV rapid
tests can be very useful in the long-term follow-up of HIV
vaccine recipients.
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